Skip to main content
. Author manuscript; available in PMC: 2020 Jul 25.
Published in final edited form as: Cell. 2019 Jul 4;178(3):699–713.e19. doi: 10.1016/j.cell.2019.06.011

Figure 4. CIRI applied to breast adenocarcinoma.

Figure 4.

A) The course of a patient with breast cancer receiving neoadjuvant chemotherapy followed by surgery is shown. Pretreatment risk factors (shown in blue) are obtained directly prior to therapy. Interim risk factors (shown in orange) are obtained after surgery, but before the eventual clinical outcome (DRFS36). B) Similar to Fig 2B and 3B, the displayed plot demonstrates the calibration of predictions from CIRI-BRCA with observed patient outcomes across predictions from all time-points. C) Bar plot demonstrates the C-Statistic and 95% confidence interval for predicting DRFS at various time-points using pretreatment risk factors, residual cancer burden and CIRI. Predictions from CIRI-BRCA are made after integration of all data. D) A Kaplan-Meier estimate shows the DRFS for patients stratified by CIRI-BRCA risk-prediction of DRFS36 split into three groups at the time of final restaging after integration of all information (i.e., inclusive of pathologic response). E) Similar to panel D, a Kaplan-Meier estimate shows the DRFS for patients stratified by CIRI-BRCA. Here, risk-predictions across all time-points are shown; split into 3-strata. (DRFS: distant relapse-free survival; DRFS36: distant relapse free survival at 36 months). * indicates P < 0.05. See also Figure S4.